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Abstract Streptozotocin (STZ), a glucosamine-nitrosourea
compound derived from soil bacteria and originally developed
as an anticancer agent, in 1963 has been found to induce
diabetes in experimental animals. Since then, systemic appli-
cation of STZ became the most frequently studied experimen-
tal model of insulin-dependent (type 1) diabetes. The com-
pound is selectively toxic toward insulin-producing pancreatic
beta cells, which is explained as the result of its cellular uptake
by the low-affinity glucose transporter 2 (GLUT2) protein
located in their cell membranes. STZ cytotoxicity is mainly
due to DNA alkylation which results in cellular necrosis.
Besides pancreatic beta cells, STZ applied systemically dam-
ages also other organs expressing GLUT2, such as kidney and
liver, whereas brain is not affected directly because blood-
brain barrier lacks this transporter protein. However, single
or double intracerebroventricular (icv) STZ injection(s) chron-
ically decrease cerebral glucose uptake and produce multiple
other effects that resemble molecular, pathological, and be-
havioral features of Alzheimer’s disease (AD). Taking into
consideration that glucose hypometabolism is an early and
persistent sign of AD and that Alzheimer’s brains present
features of impaired insulin signaling, icv STZ injections are
exploited by some investigators as a non-transgenic model of
this disease and used for preclinical testing of pharmacologi-
cal therapies for AD. While it has been assumed that icv STZ
produces cerebral glucose hypometabolism and other effects
directly through desensitizing brain insulin receptors, the ev-
idence for such mechanism is poor. On the other hand, early
data on insulin immunoreactivity showed intense insulin ex-
pression in the rodent brain, and the possibility of local
production of insulin in the mammalian brain has never been
conclusively excluded. Also, there are GLUT2-expressing
cells in the brain, in particular in the circumventricular
organs and hypothalamus; some of these cells may be
involved in glucose sensing. Thus, icv STZ may dam-
age brain glucose insulin producing cells and/or brain
glucose sensors. Mechanistic explanation of the mode
of action of icv STZ, which is currently lacking, would
provide a valuable contribution to the field of animal
models of Alzheimer’s disease.
Keywords Intracerebroventricular streptozotocin injection .
Non-transgenicAlzheimer’s diseasemodel . Insulinproducing
cells . Insulin receptors . Brain
Introduction
Laboratory animals, mostly rodents, are commonly used as
models of human diseases. The concept of such models is
based on a certain degree of Banalogy^ between pathological
processes that occur during progression of a disease in patients
and in animals being studied as their substitute [1]. Although a
model should not be considered identical to what is being
modeled, it shall include a convergent set of analogies be-
tween the Btarget^ phenomenon and the system being studied,
i.e., between a patient in whom the disease develops and an
experimental animal in which the Banalogous^ pathological
processes occur. Creation of an animal model of a human
disease requires at least some general knowledge about the
disease mechanism. Provided sufficient degree of analogy,
animal models should prove useful in efforts to understand
details of disease process and in translational research for se-
lection of experimental therapies prior to initiation of clinical
evaluation. However, if the knowledge on which the model is
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based is unreliable, exploiting it may lead to false con-
clusions. This, indeed, happens quite frequently. Experimental
treatments shown to be effective in animal studies in many
cases turn out to be ineffective, sometimes even harmful, in
clinical trials.
The case of Alzheimer’s disease (AD) is no exception.
During the first half of the 1990 decade, mutations of the three
BAlzheimer’s genes^ coding beta-amyloid precursor protein
(β-APP) and presenilins (PS-1, PS-2) have been determined
as causative in the early onset autosomal dominant forms of
this disease (familial AD) [2]. Early onset AD comprises only
some 5 % of Alzheimer’s cases; notwithstanding the above,
discovery of the Alzheimer’s genes paved the way to trans-
genic models of the disease. The first report on transgenic
mice that express high levels of human mutated β-APP and
progressively develop major pathological hallmarks of AD,
i.e., extracellular amyloid beta deposits, neuritic plaques, and
synaptic loss, was published in 1995 [3]. Since then, preclin-
ical (translational) AD research has been dominated by a few
murine transgenic models which simulate this neuropathology
and display behavioral symptoms reminiscent of AD [4].
Hundreds of candidate drugs were tested with the use of these
models, and more than 300 were found efficacious in amelio-
rating cognitive deficits, neuropathological burden of the
model disease, or both. Unfortunately, none was translated
into a successful therapy of human patients [5, 6]. Several
factors were proposed as possible root causes of this failure.
One of the most important may be the lack of robust ap-
proaches for identifying causality between multitude of
interacting processes involved in the development of the dis-
ease [7]. Indeed, the issue of causation may be critical to the
understanding pathophysiological mechanisms involved in
Alzheimer’s disease.
While transgenic models are still the mainstream of
AD research, alternative models are sought, which could
prove more useful for translational research. The expert
advisory panel gathered under the auspice of the
Alzheimer’s Drug Discovery Foundation in the report
published in 2011 [5] concluded that non-transgenic
AD models were often underused. Recently, however,
the model employing intracerebroventricular injection
of a diabetogenic toxin streptozotocin (icv STZ model)
is gaining considerable popularity. The aim of the pres-
ent paper is to compare the assumptions underlying the
icv STZ model and the transgenic models of AD and to
discuss mechanism(s) which may be involved in the
development of Alzheimer’s-like neuropathology in rodents
following single or double injection of streptozotocin into
the lateral ventricles. As will be shown, the major con-
ceptual difference between the transgenic models and
the icv STZ model concerns the place of brain glucose
hypometabolism in the chain of causation leading to the
Alzheimer’s neuropathology.
Brain Glucose Hypometabolism in Alzheimer’s Disease:
Secondary Effect or Primary Cause?
After the discovery of the Alzheimer’s genes, the leading con-
cept underlying research in the AD area has been the Bamyloid
cascade^ hypothesis proposed more than 20 years ago [8]. Its
original version had two tenets, namely (i) that intracerebral
deposition of β-amyloid (Aβ) is causative for AD pathology
and (ii) that other brain lesions such as neurofibrillary tangles,
dystrophic neurites, loss of synapses etc. follow. Since then,
the hypothesis has been subject to several modifications to
accommodate novel findings. For example, it is now assumed
that neurotoxicity is exerted not by amyloid plaques located
extracellularly but rather by intracellular fibrillary oligomeric
forms of Aβ peptide formed earlier in the course of the disease
[9]. However, the main tenet that the disease starts by Aβ
accumulation, oligomerization, and toxicity remains un-
changed. Although there must be some primary cause or trig-
ger, such as genetic factors or unknown environmental toxic-
ities, execution of neurodegeneration in AD starts at the level
of Aβ oligomers and fibrils. The chain of causation in AD
may thus be presented as shown in Fig. 1. Glucose
hypometabolism in AD-prone brain regions such as hippo-
campus, although characteristic for AD even at its very early
phase [10], is considered either the endpoint, or in any case the
secondary effect of the neurodegenerative process. Even when
not presented explicitly, such picture mirrors implicit under-
standing of the disease process. For example, in a typical
review paper [11], numerous factors, metabolic and genetic,
are listed as the causes or promoters of Aβ oligomerization
leading to deficits of neurogenesis and synaptic damage, but
„ AMYLOID CASCADE” HYPOTHESIS
Unknown primary cause(s)
APP          A Aggregates
tau       hyperphosphorylated tau
Neuronal degeneration
CMR Glucose           Dementia
Fig. 1 Diagram presenting chain of causation assumed by the Bamyloid
cascade^ hypothesis
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decreased glucose consumption is not included (Fig. 2). In
several other recent reviews which discuss possible causes
of AD, brain metabolism of glucose is also not touched
[12–15].
Decreasing brain glucose consumption is, however, a very
early sign of AD. Measurements with the 18FDG-PET tech-
nique in individuals harboring Alzheimer’s genes have shown
that signs of depressed brain glucose uptake, apparently inde-
pendent of structural atrophy, are detectable up to three decades
prior to the expected onset of clinical symptoms of early onset
familial AD [16]. Moreover, there are other tracks of connec-
tion or relation between failure of brain glucose metabolism
and Alzheimer’s disease. Incipient AD depression of brain
glucose consumption is significantly more pronounced than
depress ion of bra in oxygen consumpt ion . This
disproportionality, abnormally high ratio of oxygen metabolic
uptake to glucose metabolic uptake, has been found in the
whole brain [17, 18], and imaging of brain oxygen and glucose
consumption with positron emission tomography of oxygen-
15 and 18-fluorodeoxyglucose revealed that it originates most-
ly in the parietotemporal region of the cerebral cortex [19].
Another track comes from in vitro and in vivo experiments
in which brain glucose metabolism was blocked by metabolic
inhibitors such as 2-deoxyglucose (2-DG). In vitro experi-
ments on cells transfected with β-APP695 expresser plasmid
have demonstrated that β-APP processing to potentially
amyloidogenic COOH-terminal derivatives occurs in the en-
doplasmic reticulum or Golgi complex and is stimulated by
exposing cells to a combination of 2-DG and sodium azide
which inhibits cellular energy metabolism [20]. We [21]
injected rats intraperitoneally with 500 mg/kg 2-DG and
found that in the cerebral cortex grey matter, the level
of β-APP is increased concomitantly with increase in
the level of phosphorylated and decrease in dephosphor-
ylated tau protein. Similar changes were later found by the
others [22] following injection of single doses of 2-DG
(1 g/kg), insulin, 3-nitropropionic acid, or kainic acid to mice,
both wild-type and β-APP transgenic. Increase in brain β-
APP was accompanied by increase in Aβ and β-secretase;
these effects were attributed to pharmacological inhibition of
energy production in the brain. However, in our experiments,
2-DG injection did not result in decreased cortical ATP or
phosphocreatine, as judged from 31P-MRS spectra [21], which
result was in agreement with the earlier report showing no fall
in brain ATP assayed enzymatically following a single i.p.
dose of 3 g/kg 2-DG in mice [23]. Proamyloidogenic effects
of 2-DG may, therefore, result not from failing brain energet-
ics coupled to mitochondrial oxidative metabolism but from
decreased availability of glucose for other metabolic path-
ways, e.g., those involved in aerobic glycolysis.
In this context, it may be worth to mention that correlations
have been found between deposition of amyloid plaques and
the set of frontal and parietal midline structures with high
connectivity and high metabolic activity (see e.g., [24] and
the references quoted there). For example, Vlassenko et al.
[25] analyzed the data obtained with three PET modalities
mapping brain oxygen consumption (with 15O2), glucose con-
sumption (with 19F-deoxyglucose) and amyloid β burden
(with 13C-PIB) and found that the spatial distribution of aero-
bic glycolysis in normal young adults correlated with the lo-
cation of Aβ deposits in AD patients as well, as in cognitively
normal participants with elevated Aβ. The authors suggested
a possible link between regional aerobic glycolysis in young
adulthood and later development of Alzheimer pathology.
Considering the above, an alternative chain of causation
may be proposed for AD (Fig. 3), in which decreased ability
of brain tissues to metabolize glucose is the central point at
which execution of neurodegeneration is initiated, whereas
development of amyloid deposits and neurofibrillary tangles
built of hyperphosphorylated tau protein follow. In an analogy
to type 2 diabetes, the hallmark of which is decreased ability
of peripheral tissues to metabolize glucose, brain-specific de-
crease of the ability to metabolize glucose could be called type
3 diabetes, and indeed, such term has been proposed for
Alzheimer’s disease [26].
Streptozotocin-Based Model of Diabetes
Discussion on the streptozotocin intracerebroventricular injec-
tions (icv STZ), experimental paradigm as a model of
Alzheimer’s disease will be preceeded with a brief summary
of the history and properties of this substance. Streptozotocin
(structural formula, Fig. 4), isolated in the late 1950s from a
strain of the soil bacteria Streptomyces achromogenes, was
patented and initially developed as an antibiotic, later as an
anticancer agent. Until now, it is marginally used in the multi-
drug therapy of some rare neuroendocrine tumors [27], al-
though is much more popular in the non-clinical research,
Fig. 2 Diagram listing factors contributing to Aβ oligomerization and its
downstream effects. Reproduced from ref. 11 (open access)
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because injected intravenously or intraperitoneally induces
diabetes in experimental animals.
More than 40 years ago, it has been shown that in the rat
(Wistar strain), single intravenous injection of STZ results in
dose-dependent diabetogenic response consisting of increase
in serum glucose level and urine volume and decrease in se-
rum and pancreatic immunoreactive insulin; doses of 45–
65 mg/kg decreased insulin by more than 10 times [28].
Currently, it is accepted that intravenous or intraperitoneal
injection of STZ in dose of 40–60 mg/kg or higher is the
model of type 1 (insulin-dependent) diabetes [29, 30]. To ob-
tain a model of type 2 diabetes (non-insulin-dependent)
characterized by impaired glucose-stimulated insulin secre-
tion and insulin resistance, i.e., inadequate response to insulin
signal in muscles and other tissues, lower peripheral STZ dose
(35 mg/kg or less) is combined with high fat diet (see e.g.,
[31]).
Current understanding of the diabetogenic property of
streptozotocin and mechanisms involved has been summa-
rized by Lenzen [32, 33]. Unlike other nitrosureas which are
lipophilic and quickly taken up by cells, STZ due to hexose
substitution is less lipophilic and requires a particular glucose
transporter, GLUT2, to cross cellular membranes. Selectivity
of STZ toward insulin producing beta cells in pancreas is
explained by the presence of GLUT2 in the membranes of
vulnerable cells. Acting intracellularly methylnitrosourea
moiety of STZ alkylates DNA; cell death, which occurs by
necrosis, is the consequence of poly(ADP-ribose)polymerase
(PARP) activation with subsequent depletion of NAD+ and
ultimately depletion of ATP stores. Besides insulin-
producing pancreatic beta cells, STZ is toxic toward other
organs expressing GLUT2 transporter, particularly kidney
and liver. Brain is not affected directly because STZ is not
able to penetrate blood-brain barrier which lacks GLUT2
transporter.
Streptozotocin action is considered similar to that of the
other well-known diabetogenic substance alloxan. Both com-
pounds are taken up by GLUT2 transporters, act intracellular-
ly, are selectively toxic toward pancreatic insulin-producing β
cells, and their toxicity can be blocked by peripheral applica-
tion of non-metabolysable glucose analog 3-O-methyl-glu-
cose. However, mechanisms of their diabetogenic activity
seem to differ in some points. One difference is that D-glucose
and D-mannose are reportedly able to block toxic effect of
alloxan but not STZ [29]. The other concerns chemical stabil-
ity: At pH 7.4 and 37 °C, alloxan is very unstable with half-life
of 1.5 min; STZ is thought to be relatively stable for at least
1 h [33], although the other source indicates its half-life in
solution at physiological pH as 19 min [34].
Cytotoxicity of STZ is dependent on the activity of poly
(ADP-ribose) polymerase (PARP), and PARP-knockout mice
are resistant to this toxin [35, 36]. Currently accepted view is
that PARP activation in various pathophysiological situations
is the consequence of increased tissue ROS generation [37]. In
the long term, animals made chronically hyperglycemic by
STZ develop oxidative stress because hyperglycemia in-
creases generation of free radicals [38]). Likewise, although
diabetes induced in rodents by systemic STZ injection affects
several aspects of central nervous system metabolism and
function (see, for example [39, 40]), it is implicitly assumed
that all central nervous system effects of STZ given peripher-
ally are indirect, i.e., can be attributed to chronic hyperglyce-
mia and its sequelae such as tissue oxidative stress, etc.
GLUT2 glucose transporting protein is a part of the distrib-
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Fig. 3 Diagram presenting chain of causation assumed by the Bcerebral
glucodeprivation^ hypothesis
Fig. 4 Structural formula of streptozotocin (STZ)
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pancreatic beta cells and some other organs, e.g., liver [41].
GLUT2 is also expressed in the brain, in particular in hypo-
thalamus and brainstem, where it is encountered in neurons,
astrocytes, tanycytes, and epithelial cells lining the cerebral
ventricles (see references cited in [42]). Of these cells, hypo-
thalamic glucose-sensing neurons are located inside the
blood-brain barrier. However tanycytes, a particular type of
glial cells located in the circumventricular organs devoid of
blood-brain barrier [43], are suspected to be able to sense
blood glucose level in both cerebrospinal fluid and blood
[44, 45].
Intracerebroventricular Administration of Streptozotocin
and Alloxan: Similarities and Differences
Intracerebroventricular instillations of drugs are rarely used in
the clinic for administering drugs [46]; more frequently, drugs
or selective toxicants are applied to the brain ventricular sys-
tem of laboratory animals for experimental purposes.
Injections are mostly performed into the lateral ventricles.
Although, as pointed out by Pardridge [47], drug injected into
the cerebrospinal fluid will rapidly move into the blood via
bulk flow but will poorly penetrate into the brain tissue owing
to limitations of diffusion, many investigators assume that
intracerebroventricular (icv) administration allows high con-
centrations to enter the central compartment because it by-
passes the blood-brain barrier and other mechanisms that limit
distribution of the administered substance into the brain.
More than 30 years ago, icv injections of alloxan were
used, apparently for the first time, in experiments aimed at
elucidating intracerebral glucose sensing and its physiological
role [48]. Interestingly, Ritter et al. [49] reported soon after
that alloxan injections into the lateral ventricles (dose 40 μg in
5 mL) result in marked reduction of glucoprivic feeding
evoked by subcutaneous 2-deoxyglucose or insulin, whereas
icv streptozotocin in doses up to 400 μg were ineffective. No
explanation for the different reaction to alloxan and
streptozotocin has been provided, but in further studies of
cerebral glucosensing, neurons icv alloxan injections have
been preferred [50]. Currently, it is believed that cerebral glu-
cose sensing is involved in the control of feeding behavior,
peripheral glucose homeostasis, and thermoregulation. Its cel-
lular mechanisms are far from being understood, but by anal-
ogy to pancreatic β cells, it is supposed by some investigators
that they involve GLUT2 glucose transporter [51].
Lacković and Salković [52] compared the effects of periph-
eral and intracerebroventricular alloxan and streptozotocin on
rat brain monoamines. Eight days after subcutaneous admin-
istration of the diabetogenic doses of alloxan increased brain
serotonin, dopamine and noradrenaline were noted, but no
such effect occurred after intraperitoneal injections of diabe-
togenic doses of streptozotocin. However, the effects of icv
alloxan and STZ were similar. On the other hand, further re-
search has revealed that icv administration of alloxan does not
alter rat memory and learning functions assessed with behav-
ioral tests 3 months later [53], whereas icv STZ resulted in
cognitive deficits which became evident 2 weeks after the
treatment and persisted at least up to 3 weeks post-treatment
[54]. Likely because of this difference, the cause of which
also remains unexplained, icv streptozotocin but not icv
alloxan has been developed as a non-transgenic model of
Alzheimer’s disease.
Intracerebroventricular Streptozotocin: a Metabolic
Model of Alzheimer’s Disease
The pioneer of the icv STZmodel is Professor Sigfried Hoyer.
His early works on this subject have been summarized in the
paper published in 1994 [55]. Current status of the concept
that icv STZ is the non-transgenic metabolic model of sporad-
ic AD has been presented in the review with his coauthorship,
published in January 2013 [56].
The starting point of the reasoning developed by Hoyer
was that in the sporadic Alzheimer’s disease, there is a fall
in brain consumption of both oxygen and glucose, but a fall in
brain oxygen consumption is disproportionately slighter.
These observations led to the hypothesis that the major bio-
chemical perturbation in incipient sporadic AD concerns the
control over cerebral glucose metabolism, which is subse-
quent to a signal transduction failure of the cerebral insulin
receptor. At this point, another observation was also taken into
account, namely that in adult male Wistar rats, intracerebro-
ventricular administration of 80 mU insulin stimulated two
key glycolytic enzymes, hexokinase and phosphofructoki-
nase, by approx. 20 %. This later result was interpreted as
the evidence for the control of glycolytic flux in the brain by
insulin and led to the conclusion that any perturbation in in-
sulin signal transduction will have severe impact on brain
glucose metabolism [57]. The next step was to administer
streptozotocin intraventricularly, in order to damage the con-
trol level of cerebral glucose/energy metabolism. In the
other paper from the Hoyer’s group [58], the purpose of
the study was defined as to investigate whether or not
cerebral glucose utilization is changed locally after intra-
cerebroventricular (icv) STZ administered in a subdiabetogenic
dosage (1.5 mg/kg bw.). These and other similar experiments
have shown that application of STZ to the rat lateral
ventricles decreased brain glucose utilization, in partic-
ular in the frontal and parietal cortex, decreased ATP and
phosphocreatine concentrations, ATP/ADP ratio, and the en-
ergy charge potential in the cerebral cortex [59], and produced
several other brain metabolic and behavioral disturbances. In
one paper [60], it was hypothesized that triple icv STZ
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injections inhibit cerebral insulin receptors, but no mechanis-
tic explanation was provided for such effect.
Based on the close analogy between human patients with
AD and rats subjected to icv STZ injections in respect to brain
metabolic and behavioral disturbances, Hoyer proposed that
icv STZ shall be recognized as the non-transgenic preclinical
model of Alzheimer’s disease. In the most recent review [56],
this opinion is further extended by the statement that sporadic
AD as well as its model obtained by icv injection of STZ are
being recognized as an insulin resistant brain state (IRBS).
However, the exact nature of IRBS is only vaguely defined.
The preceding review dedicated to the hypothetical concept of
IRBS as the cause of Alzheimer disease [61] explains that
functionally, the IRBS may correspond to the pathophysiolo-
gy of diabetes mellitus type II. However, in the case of spo-
radic AD, the authors propose the term IRBS instead of
Bdiabetes mellitus type II confined to the brain^ to avoid mis-
understandings. Recent reviews dedicated to the IRBS con-
cept written by the others [62, 63] also do not include rigorous
definition of this term. One may guess that IRBS is a brain
analog of insulin resistance syndrome (IRS) of peripheral tis-
sues, a condition characterized by decreased tissue sensitivity
to the action of insulin and leading to a compensatory increase
in insulin secretion [64]. It shall be noted, however, that in the
(peripheral) IRS, chronic hyperisulinemia in blood occurs
concomitantly with reduced insulin levels in the central ner-
vous system, explained its by reduced delivery from pancre-
atic source [65].
Development of several Alzheimer-like indices of brain
metabolic and behavioral disturbances in rats subjected to
one or two icv STZ injection(s) is considered to be a dynamic
process. In the majority of papers, the effects of icv STZ on
brain function and behavior were followed within a relatively
short time of a few weeks. Only recently, the Hoyer’s group
reported on the longer follow-up of icv STZ rats which re-
vealed deposits of amyloid β in the wall of meningeal and
cortical blood vessels visualized by thioflavine-S and Congo
red as well, as by immunohistochemical staining [66]. In one
of the most recent reviews [56], it is stated that cognitive and
neurochemical changes triggered by icv STZ injection(s) fol-
low a time-dependent pattern which consists of three phases.
Within 1 month, an acute response develops, at 1 to 3 months,
a tendency to return to normal values takes place and finally, at
6 to 9 months, decompensation phase occurs with a slow and
progressive aggravation. This temporal evolution of patholo-
gy initiated by (single or double) streptozotocin injection into
the lateral ventricles seems to resemble the situation in a real
life which does not exist in the transgenic mice AD models.
The other authors also reported on various neurochemical
and neuropathological consequences of icv STZ injection(s).
Most observations were convergent with the Hoyer’s obser-
vations that metabolic disturbances following icv STZ cover
large areas of the brain, including locations distant from the
injection site, and that they mount up in time. For example,
two daily injections of STZ into the lateral ventricles of adult
rats caused in the frontoparietal cortex a significant enlarge-
ment of the neuronal Golgi apparatus detected 3 weeks later
[67], and similar experimental paradigm led to indiscriminate
lowering of most proton magnetic resonance lines recorded
from the 27 μL tissue volume which included hippocampus
and a part of cerebral cortex [68] (Fig. 5). Five weeks after a
single bilateral icv STZ injection (3 mg/kg), Coreia et al. [69]
have found a decrease in brain weight, a cognitive decline, a
significant increase in hippocampal Aβ (1–42), and increase
in both hippocampal and cortical hyperphosphorylated tau
levels. Another important features of rat icv STZmodel which
resemble findings in brains from AD patients are signs of
brain tissue oxidative stress (see e.g., [70]) and brain mito-
chondrial abnormalities which may cause caspase-mediated
apoptotic cell death [71, 72]. Mitochondrial abnormalities
and tissue oxidative stress may be related, although according
to a recent data [73] glial activation, TNF-α and free radical
generation following icv STZ occurs earlier than apoptosis
and synaptic neurotoxicity. In the other study [74], in rats after
icv STZ, different types of behavioral and neurodegenerative
responses have been observed with distinct time courses rang-
ing from 1 h to 15 days.
In the brains of adult icv STZ-treated rats, Deng et al. [75]
found impaired insulin signaling, overactivation of glycogen
synthase kinase-3β, decreased levels of major brain glucose
transporters, downregulated protein O-GlcNAcylation, as
well as increased phosphorylation of tau and neurofilaments
and decreased microtubule-binding activity of tau. These au-
thors suggested that the key mechanism in the development of
disease in the human AD, as well as in the rodent model
disease is the development of brain insulin resistance which
leads to neurofibrillary degeneration via two cooperating path-
ways, namely decreased PI3K-AKT signaling activity and
glycogen synthase kinase 3 beta (GSK3β) overactivation
and decreased GLUT1/3 expression and decreased
intraneuronal glucose metabolism. More recently, investiga-
tors from the same laboratory [72] compared the non-
cognitive and cognitive behaviors as well as biochemical
and immunohistochemical alterations in brains of a transgenic
and a non-transgenic murine model of AD, 3xTg-AD mice
which harbor mutated presenilin 1, APP, and tau genes and
icv STZ mice, respectively. The conclusion was that both
models demonstrated similar behavioral patterns, whereas
they differed in some neuropathological features; the most
prominent brain abnormality in the icv STZ model was neu-
roinflammation, whereas in the transgenic model, it was ele-
vation of hyperphosphorylated tau. Finally, Chen et al. [76]
observed that icv STZ injection exacerbates memory distur-
bances and Alzheimer-like neurochemical changes in brains
of 3xTg-ADmice, concluding that these findings demonstrate
the role of metabolic insult in AD pathology in vivo.
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Recently, de la Monte [77] and de la Monte and Tong [78]
pursued the concept of Alzheimer’s disease being type 3
(brain-specific) diabetes. Whereas this idea stemmed from
clinical observations suggestive of that AD is a metabolic
disease in which brain cannot efficiently utilize glucose, ex-
perimental observations of impairments of insulin, as well as
insulin growth factors (IGF-1, IGF-2) signaling following icv
STZ in rat pups [79, 80] were interpreted as providing the
strongest evidence favoring this concept. Interestingly, in
these experiments, a significant atrophy of the whole brain
was observed 3 weeks after icv STZ injection [79].
However, the results obtained by some other authors are
suggestive of spatial restriction of intracerebral damage
caused by STZ injection into lateral ventricles. For example,
Terwel et al. [81] injected adult rats intracerebroventricularly
with STZ and 3 weeks later investigated activities of chosen
enzymes in two brain areas and found that in the septum
activities of all enzymes except choline acetyltransferase
Fig. 5 Effects of icv STZ
(bilaterally, 3 mg/kg body weight,
on days 1 and 3) on
concentrations of brain
metabolites obtained from
1H-MRS spectra recorded from
27 μL volume comprising
hippocampus and part of the
cerebral cortex, in 7 T magnetic
field strength with very short echo
time. a 2 weeks after and b
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phosphocholine, n=8, error bars
show standard deviations,
asterisks indicate p<0.05 by
two-tailed t test for independent
means. (Reproduced from ref. 68,
with permission from
Springer-Verlag)
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(ChAT) were decreased, whereas in the hippocampus the de-
crease was limited to ChAT. Moreover, in icv STZ-injected
animals, the septum weight was reduced whereas the hippo-
campus weight was unchanged. These findings were
interpreted as suggestive of that STZ injected into the lateral
ventricles acts as a non-selective neurotoxin near the site of
injection; sparing septal ChAT activity could be explained by
the more distant location of the septal cholinergic neurons to
the injection site. Shoham et al. [82] provided histopatholog-
ical evidence that damage caused by icv STZ is restricted to
axons and myelin of the fornix, anterior hippocampus and
periventricular structures known to be essential for learning
and spatial memory. They concluded that learning deficits
caused by icv STZ may not be caused only by impairing brain
glucose utilization. More recently, Kraska et al. [83] reported
that in rats, the extent and dynamics of brain neurodegenera-
tion following icv STZ injection depends on the amount of the
toxin injected. Higher dose (1 mg/kg) induced severe and
acute neurodegenerative lesions in the septum and corpus
callosum, which were associated with inflammation and
might have been caused by local oxidative stress, whereas
lower dose led to less severe but more chronic and widespread
effects.
Does icv STZ Cause Brain Insulin Receptors
Desensitization Directly? Are Other Explanations
Plausible?
It is frequently assumed that streptozotocin injected intraven-
tricularly damages or desensitizes brain insulin receptors or
otherwise produces brain insulin resistance defined as inade-
quate response of insulin receptors located in the brain to
insulin. This interpretation is sometimes presented as an anal-
ogy between the mechanism of action of icv STZ on the brain
and the mechanism of peripheral action of low doses of STZ.
For example, in the (already brought up several times) author-
itative review on the icv STZ model of AD, Salkovic-Petrisic
et al. [56] opined that multiple parenteral treatment with low to
moderate STZ doses causes insulin resistance by damaging
insulin receptor (IR) signaling. The problem with this state-
ment is that STZ given peripherally does not damage insulin
receptor signaling directly. Three references quoted there to
support such opinion [84–86] describe experiments in which
rats were made severely diabetic by injecting peripherally
high streptozotocin doses: 45, 65, and 100 mg/kg, respective-
ly. Moreover, all these experiments showed that development
of in vivo insulin resistance in peripheral tissues following
subcutaneous or intravenous STZ injection is secondary to
insulin deficiency in blood and hyperglycemia. For example,
in the abstract of their paper, Blondel and Portha [84] wrote
that insulin deficiency and concomitant hyperglycemia, as the
consequences of streptozotocin administration in the adult rat,
rapidly lead to the development of in vivo insulin resistance,
first in the liver and later on in the peripheral tissues.
It shall also be taken into account that insulin receptors, at
least in some extracranial locations, are subject to intracellular
turnover, being continuously synthesized, deposited in cell
membranes, endocytosed, and degraded with a relatively short
half-life of hours rather than days (for example, 6.7 h in dif-
ferentiating adipocytes [87]). If similar IR turnover operates in
the brain, inflicting IR damage but leaving cells bearing these
receptors intact would result in their rather quick regeneration.
Last but not least, STZ molecule is structurally very different
from insulin molecule, and there is no apparent reason to
expect interaction between STZ and IR. It seems that the hy-
pothesis of IR damage throughout the brain caused directly by
single or double intracerebroventricular injection of STZ can-
not explain the apparent irreversibility and long-lasting pro-
gression of the evoked effects.
Of note is also that brain neuron-specific insulin receptor
knockout (NIRKO) mice, which exhibit a complete loss of
insulin-mediated activation of phosphatidylinositol 3-kinase,
were reported to display markedly reduced phosphorylation of
Akt and GSK3 beta kinases leading to substantially increased
phosphorylation of Tau protein but exhibited no alteration in
neuronal proliferation/survival, memory, or basal brain glu-
cose metabolism [88].
The next relevant issue is that of the diffusion of
streptozotocin after intracerebrovientricular injection. As
pointed out by Pardridge [47], drug injected into the cerebro-
spinal fluid will rapidly move into the blood via bulk flow but
will poorly penetrate into the brain tissue owing to limitations
of diffusion. Data obtained recently with fluorescent tracers of
differing molecular weights injected into the lateral ventricle
of mice [89] indicate that substances injected into ventricular
CSF only minimally enter brain parenchyma and remain con-
fined to the immediate periventricular region. Therefore, it is
not possible that single injection of STZ into the lateral ven-
tricles evokes metabolic and cytoarchitectonic responses in
such distant locations as frontal or parietal cortex through
damaging insulin receptors which are present there. It may
be concluded that the hypothesis that streptozotocin injected
once or twice to the cerebral lateral ventricles damages insulin
receptors throughout the brain acting directly on them is not a
plausible explanation.
The other issue which deserves reflection in the context of
icv STZ model of AD is the possibility of intracerebral syn-
thesis of insulin in mammals. In a classical study of
Havrankova et al. [90], no change in either brain insulin or
brain insulin receptors was found within up to 30 days after
injection of a diabetogenic peripheral STZ dose which led to
depletion of insulin in pancreas and blood. Later, it was found
that insulin concentrations in brain displayed no relationship
to the serum or CSF insulin levels [91]. These observations
were taken as the evidence for insulin synthesis in the brain.
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Most of the further research did not confirm such hypothesis,
and many authors believe that all insulin found in mammalian
brains comes from pancreas (see e.g., [92]). However, others
are not certain (see e.g., [62]). Schechter et al. [93], using
insulin knockout mice able to survive only 3 days after birth,
provided evidence for a role of insulin within the brain in
maintaining a balance in phosphorylation of neuronal cyto-
skeleton and pointed out that pancreatic insulin with its short
half-life of a couple of minutes would be a difficult source to
constantly maintain the cytoskeleton equilibrium.
Involvement of GLUT2 as mediator of icv STZ effects has
been postulated [83, 94, 95]. GLUT2 is the isoform present in
pancreatic insulin producing cells and also involved in glu-
cose sensing. Within the body, there is a distributed system of
glucose sensors, and part of this system is located in the brain
[42]. GLUT2 protein immunoreactivity has been detected in
many brain areas [96]. In particular, a subpopulation of
ependymal cells called tanycytes, located in the lateral ventri-
cles and other circumventricular organs, contain high density
of GLUT2 protein, and studies have shown that these trans-
porters are functional [97]. It may be expected that, due to
their location close to the injection site, tanycytes are prefer-
entially damaged by a single icv STZ injection. Some re-
searchers postulated that these cells monitor glucose levels
in both CSF and plasma. What happens if they are irreversibly
damaged by a single or double icv STZ injection and signals
which they deliver to the hypothalamic integrator vanish?
Almost 30 years ago, Coimbra and Migliorini [98]
discovered that microinjections of minute amounts of
2-deoxyglucose into the preoptic area of fed rats induced
rapid increases in blood plasma free fatty acids (FFAs), where-
as glucose remained unchanged. Acute exposure to free fatty
acids is known to cause insulin resistance in muscle [99], and
FFA are able to cross blood-brain barrier [100]; moreover, they
are implicated in the generation of the amyloid peptides in the
brain [101, 102]. It is tempting to speculate that single or dou-
ble icv STZ injection may chronically influence metabolism in
brain regions distant from injection site indirectly, through
changes in plasma level of FFA or other substances potentially
toxic to the brain. Another mechanism by which changes in
plasma content could possibly influence brain glucose metab-
olism may involve neurotoxic ceramides which may enter
brain from blood through blood-brain barrier and induce brain
insulin resistance, inflammation, and cell death [103].
Although involvement of the aforementioned mechanisms is
currently not supported by any direct evidence, a possibility of
some extracranial mechanisms contributing to the central ef-
fects of streptozotocin injected intracerebroventricularly
should not be a priori excluded. Interestingly, although intra-
peritoneal and intracerebroventricular injection(s) of STZ are
known to produce different effects on brain metabolism, in the
case of another nitrosamino compound N-nitrosodiethylamine
(NDEA), the effects were similar [104].
In summary, there is no doubt that single or double injec-
tion of streptozotocin into the lateral ventricles of rat produces
chronic metabolic, neuropathological, and behavioral distur-
bances reminiscent of human Alzheimer’s disease, but accept-
able mechanistic explanation for these phenomena is lacking.
The concept of irreversible inhibition or desensitization of
insulin receptors caused directly by STZ diffusing throughout
the brain parenchyma does not seem plausible, and alternative
explanation(s) shall be sought. Understanding causality be-
tween multitude of interacting processes involved in the de-
velopment of the model disease evoked by icv STZ injec-
tion(s) is necessary for assessment of its convergence with
the human sporadic Alzheimer’s disease and possible useful-
ness in translational research.
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